184 related articles for article (PubMed ID: 35493483)
1. High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis.
Bronte G; Petracci E; De Matteis S; Canale M; Zampiva I; Priano I; Cravero P; Andrikou K; Burgio MA; Ulivi P; Delmonte A; Crinò L
Front Immunol; 2022; 13():866561. PubMed ID: 35493483
[TBL] [Abstract][Full Text] [Related]
2. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
[TBL] [Abstract][Full Text] [Related]
3. The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis.
Bronte G; Calabrò L; Olivieri F; Procopio AD; Crinò L
Clin Exp Med; 2023 Sep; 23(5):1551-1561. PubMed ID: 36401744
[TBL] [Abstract][Full Text] [Related]
4. MDSC subtypes and CD39 expression on CD8
Koh J; Kim Y; Lee KY; Hur JY; Kim MS; Kim B; Cho HJ; Lee YC; Bae YH; Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Eur J Immunol; 2020 Nov; 50(11):1810-1819. PubMed ID: 32510574
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients.
Adamo A; Frusteri C; Pilotto S; Caligola S; Belluomini L; Poffe O; Giacobazzi L; Dusi S; Musiu C; Hu Y; Wang T; Rizzini D; Vella A; Canè S; Sartori G; Insolda J; Sposito M; Incani UC; Carbone C; Piro G; Pettinella F; Qi F; Wang D; Sartoris S; De Sanctis F; Scapini P; Dusi S; Cassatella MA; Bria E; Milella M; Bronte V; Ugel S
Oncoimmunology; 2023; 12(1):2253644. PubMed ID: 37720688
[TBL] [Abstract][Full Text] [Related]
6. Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.
Yamauchi Y; Safi S; Blattner C; Rathinasamy A; Umansky L; Juenger S; Warth A; Eichhorn M; Muley T; Herth FJF; Dienemann H; Platten M; Beckhove P; Utikal J; Hoffmann H; Umansky V
Am J Respir Crit Care Med; 2018 Sep; 198(6):777-787. PubMed ID: 29617574
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.
Li R; Salehi-Rad R; Crosson W; Momcilovic M; Lim RJ; Ong SL; Huang ZL; Zhang T; Abascal J; Dumitras C; Jing Z; Park SJ; Krysan K; Shackelford DB; Tran LM; Liu B; Dubinett SM
Cancer Res; 2021 Jun; 81(12):3295-3308. PubMed ID: 33853830
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: systematic review and meta-analysis.
Möller M; Orth V; Umansky V; Hetjens S; Braun V; Reißfelder C; Hardt J; Seyfried S
Front Immunol; 2024; 15():1403771. PubMed ID: 38855104
[TBL] [Abstract][Full Text] [Related]
10. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
Gaißler A; Bochem J; Spreuer J; Ottmann S; Martens A; Amaral T; Wagner NB; Claassen M; Meier F; Terheyden P; Garbe C; Eigentler T; Weide B; Pawelec G; Wistuba-Hamprecht K
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286306
[TBL] [Abstract][Full Text] [Related]
11. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
[TBL] [Abstract][Full Text] [Related]
12.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
13. Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells' Subpopulations in the Peripheral Blood of Patients with Non-Small Cell Lung Cancer.
Koinis F; Vetsika EK; Aggouraki D; Skalidaki E; Koutoulaki A; Gkioulmpasani M; Georgoulias V; Kotsakis A
J Thorac Oncol; 2016 Aug; 11(8):1263-1272. PubMed ID: 27178984
[TBL] [Abstract][Full Text] [Related]
14. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
15. Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy.
Tomela K; Pietrzak B; Galus Ł; Mackiewicz J; Schmidt M; Mackiewicz AA; Kaczmarek M
Cells; 2023 Mar; 12(5):. PubMed ID: 36899926
[TBL] [Abstract][Full Text] [Related]
16. Immunoregulation and Clinical Implications of ANGPT2/TIE2
Lauret Marie Joseph E; Laheurte C; Jary M; Boullerot L; Asgarov K; Gravelin E; Bouard A; Rangan L; Dosset M; Borg C; Adotévi O
Cancer Immunol Res; 2020 Feb; 8(2):268-279. PubMed ID: 31871121
[TBL] [Abstract][Full Text] [Related]
17. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors.
Bronte G; Verlicchi A; De Matteis S; Rossi A; Affatato A; Sullo FG; Gianni C; Canale M; Burgio MA; Delmonte A; Milella M; Crinò L
Front Immunol; 2021; 12():672219. PubMed ID: 34122429
[TBL] [Abstract][Full Text] [Related]
19. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
[TBL] [Abstract][Full Text] [Related]
20. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]